Stock listing

NASDAQ:IXHL Incannex Healthcare Inc. Stock

Home listing (NASDAQ) of Incannex Healthcare Inc.

Follow Incannex Healthcare Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:IXHL

$1.86 USD +0.11 (+6.3%)

Close on Nov 20, 2026

Past year -81.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.69 – $1.99 USDNov 20, 2026
Volume
219,817 sharesNov 20, 2026
Market cap
$23.33M USDAt the close on Nov 20, 2026 · price × 12.54M shares outstanding
52-week range
$1.61 – $14.91 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$258,425 USDMedian day 68,300 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Incannex Healthcare Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:IXHL · Home$1.86 USD+0.11 (+6.3%)219,817$1.75$1.99$1.69$1.75Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IXHL · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.86+0.11+6.3%$1.75$1.99$1.69219,817
$1.75+0.01+0.6%$1.71$1.987$1.61233,831
$1.74-0.19-9.8%$1.90$1.906$1.72158,657
$1.93-0.04-2.0%$1.90$2.01$1.90111,040
$1.97-0.05-2.5%$1.984$2.07$1.91100,222
$2.02+0.045+2.3%$1.99$2.06$1.955103,637
$1.975-0.035-1.7%$2.06$2.10$1.9665,176
$2.01-0.18-8.2%$2.21$2.21$1.96184,705
$2.19-0.05-2.2%$2.28$2.28$2.1688,914
$2.24-0.03-1.3%$2.32$2.32$2.16106,215
$2.27-0.22-8.8%$2.48$2.64$2.24119,537
$2.49-0.015-0.6%$2.55$2.661$2.4936,452
$2.505+0.125+5.3%$2.40$2.55$2.4065,963
$2.38-0.14-5.6%$2.55$2.633$2.17148,804
$2.52-0.06-2.3%$2.58$2.617$2.50102,450
$2.58-0.13-4.8%$2.685$2.737$2.5853,307
$2.71+0.09+3.4%$2.65$2.79$2.6247,726
$2.62+0.01+0.4%$2.56$2.69$2.5664,568
$2.61-0.03-1.1%$2.64$2.67$2.58856,595
$2.64+0.04+1.5%$2.58$2.69$2.5738,536
$2.60-0.16-5.8%$2.73$2.75$2.55138,400
$2.76+0.015+0.5%$2.78$2.81$2.7530,700
$2.745-0.015-0.5%$2.74$2.86$2.73551,200
$2.76-0.06-2.1%$2.80$2.85$2.7568,300
$2.82-0.06-2.1%$2.88$2.939$2.81528,800
$2.88+0.02+0.7%$2.84$2.90$2.7586,700
$2.86-0.05-1.7%$2.91$2.93$2.8479,500
$2.91+0.01+0.3%$2.95$2.991$2.8857,300
$2.90-0.20-6.5%$3.04$3.10$2.85148,600
$3.10-0.10-3.1%$3.17$3.243$3.08843,400
$3.20+0.02+0.6%$3.17$3.25$3.1347,600
$3.18+0.01+0.3%$3.134$3.20$3.1326,400
$3.17-0.04-1.2%$3.20$3.30$3.1362,200
$3.210.000.0%$3.18$3.23$3.1527,900
$3.21-0.04-1.2%$3.32$3.332$3.2052,100
$3.25+0.01+0.3%$3.23$3.33$3.2041,000
$3.24-0.07-2.1%$3.35$3.35$3.2035,900
$3.31+0.16+5.1%$3.18$3.35$3.15743,700
$3.15-0.17-5.1%$3.26$3.27$3.13130,200
$3.32-0.08-2.4%$3.38$3.38$3.26145,200
$3.40-0.045-1.3%$3.47$3.47$3.36560,000
$3.445+0.05+1.5%$3.38$3.54$3.3773,600
$3.395-0.095-2.7%$3.48$3.60$3.3863,000
$3.49-0.15-4.1%$3.64$3.72$3.4890,100
$3.64+0.05+1.4%$3.58$3.72$3.4292,200
$3.59-0.21-5.5%$3.79$3.79$3.421184,800
$3.80+0.35+10.1%$3.45$3.84$3.45382,100
$3.45+0.16+4.9%$3.29$3.52$3.29128,300
$3.29+0.03+0.9%$3.29$3.40$3.2584,200
$3.26+0.01+0.3%$3.25$3.32$3.2058,200
$3.25+0.02+0.6%$3.23$3.345$3.1750,800
$3.23-0.14-4.2%$3.33$3.398$3.2236,800
$3.37+0.125+3.9%$3.30$3.443$3.2649,500
$3.245-0.005-0.2%$3.22$3.31$3.2245,800
$3.25-0.02-0.6%$3.27$3.294$3.1377,200
$3.27+0.09+2.8%$3.20$3.33$3.19134,200
$3.18-0.17-5.1%$3.35$3.40$3.17157,200
$3.35-0.29-8.0%$3.58$3.615$3.3580,000
$3.64-0.05-1.4%$3.70$3.785$3.5842,700
$3.69-0.01-0.3%$3.71$3.76$3.6560,600
$3.70-0.05-1.3%$3.71$3.85$3.6987,800
$3.75+0.13+3.6%$3.61$3.94$3.61201,200
$3.62+0.05+1.4%$3.51$3.66$3.4160,800
$3.57-0.05-1.4%$3.62$3.65$3.51470,200
$3.62+0.18+5.2%$3.38$3.62$3.3576,900

Splits

1 split · NASDAQ:IXHL · every price before a split is adjusted for it

DayRatioWhat
1-for-30Consolidation
Ticker
NASDAQ:IXHL
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Incannex Healthcare Inc. news

Incannex Healthcare Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
22 in the last 12 months · 120 in all · newest Oct 1, 2026 · oldest 2022
Decks
7 decks · latest Mar 12, 2026

Where Incannex Healthcare Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:IXHL · Home listing · This pageNASDAQUnited StatesUSD
BOATS:IXHLBOATSUnited StatesUSD

Valuation

Price/book 0.3× against a median of 1.4×: the lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$44.85M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.98

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Incannex Healthcare Inc. · NASDAQ:IXHLUS$23.33M−US$44.85Mn/an/an/a0.3×n/a0.0×0.98
Original Biomedicals Co Ltd · TPEX:6483US$23.81MUS$21.67Mn/a1,875×n/a7.1×n/a0.0×n/a
Sernova Biotherapeutics Inc · TSX:SVAUS$23.70MUS$25.46Mn/an/an/an/an/an/a0.40
Scynexis, Inc. · NASDAQ:SCYXUS$23.69M−US$21.66Mn/a−1.1×n/a0.4×−53.5%0.0×1.76
ImmuPharma plc · LSE:IMMUS$23.68MUS$22.77Mn/an/an/a9.9×n/a0.0×n/a
Organoidsciences Ltd. · KRX:476040US$23.46MUS$6.52Mn/a3.8×n/a1.1×−814.8%0.4×n/a
Immutep Ltd · ASX:IMMUS$23.41M−US$24.93Mn/a−2.6×n/a0.6×−544.8%0.0×n/a
ABVC BioPharma, Inc. · NASDAQ:ABVCUS$23.37MUS$25.81Mn/an/an/a1.8×n/a0.2×1.39
Actinogen Medical Limited · ASX:ACWUS$23.08MUS$15.17Mn/an/an/a1.6×n/a0.2×n/a
BioNxt Solutions Inc · CSE:BNXTUS$22.78MUS$22.72Mn/an/an/an/an/an/a0.22
Polyrizon Ltd. · NASDAQ:PLRZUS$22.61MUS$7.56Mn/an/an/a0.9×n/a0.0×0.67
Median of the othersUS$23.44MUS$18.42M1.4×1.4×−544.8%0.0×0.67

Forecasts

1 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
18.17 USD · Analysts' mean
EPS, year to Jun 2027
-2.23 · 1 analyst

Team and board

Officers

OfficerRole
Joel LathamPresident and Chief Executive Officer
Joseph SwanChief Financial Officer
Parisa AsvadiVice President, Research and Development
Lekhram ChangoerChief Technology Officer
Lou BarbatoChief Medical Officer
Mark BleackleyChief Scientific Officer
Natalie MayHead of Clinical Operations

Board

DirectorRole
Troy ValentineBoard Chair
George AnastassovBoard Member
Joel LathamPresident and Chief Executive Officer
Peter WiddowsBoard Member
Robert ClarkBoard Member

Events

QuarterResultsShare move
Q1 2027Nov 12, 2026 · Before open+2.3%
Q4 2026Sep 25, 2026 · Before open−2.4%
Q3 2026May 15, 2026 · Before open+2.1%
Q2 2026Feb 13, 2026 · Before open0.0%
Q1 2026Nov 14, 2025 · Before open−1.4%
Q4 2025Sep 29, 2025 · After close−10.6%
Q3 2025May 15, 2025 · Before open−61.6%
Q2 2025Feb 14, 2025 · Before open−0.9%
Q1 2025Nov 14, 2024 · After close−14.5%
Q2 2024Feb 26, 2024 · Before open+2.1%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (March 2026)Investor deck36 slidesMar 12, 2026
Investor Presentation (February 2026)Investor deck27 slidesFebruary 2026
Corporate Update (May 2023)Corporate update32 slidesMay 18, 2023
Technical Presentation (May 2023)Technical16 slidesMay 3, 2023
Investor Presentation (August 2022)Investor deck36 slidesAug 9, 2022
Technical Presentation (June 2022)Technical28 slidesJun 3, 2022
Merger or Acquisition (May 2022)Merger or acquisition27 slidesMay 12, 2022

Open Decks

Financings

RaiseDate
At-the-market programme of shares of common stock
Tranche closed: at-the-market programme
Jul 31, 2025
At-the-market programme of shares sold through At-The-Market (ATM) facility
Closed: at-the-market programme
Use of proceeds: To fund the cancellation of all remaining Series A Warrants
Jun 12, 2025
At-the-market programme of shares sold through at-the-market (ATM) facility
Closed: US$16.7M raised
Use of proceeds: $12.5 million to cancel up to 50.4% of the Series A Warrants issued in a prior financing, reducing potential dilution
May 20, 2025
Private placement of common stock (or common stock equivalents) and Series A common stock warrants
Announced: about US$12.5M · US$1.08 a share · ½ warrant at US$2.16 for 30 months · R. F. Lafferty & Co., Inc.
Dealers: R. F. Lafferty & Co., Inc. (lead)
Use of proceeds: Clinical trials incl. IHL-42X U.S. Phase 2 completion and Phase 3 expansion, repaying convertible debentures, working capital and general corporate purposes
Mar 7, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Withdrawn on Jan 21, 2022. Filed with the SEC to go public on Aug 17, 2021.

ADSs offered
2,600,000 American depositary shares
Underwriters' option
Up to 390,000 more ADSs
Listing
IXHL on the Nasdaq Capital Market · Has applied to list
Underwriter
Roth Capital Partners

Steps

StepWhen
Filed publiclyAug 17, 2021
Amended 4 timesNewest Dec 7, 2021
Filing withdrawnJan 21, 2022

Open IPO · From the cover of the amended prospectus (F-1/A) filed Dec 7, 2021

Financials

Annual, in USD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue086.0K12.0K1.01M785.2K1.90M599.7K1.18M1.01M283.0K
Cost of revenue240.0K246.0K103.0K88.1K6.33K912.0K446.5K583.2K522.8K518.3K
Gross profit-240.0K-160.0K12.0K-88.1K778.8K985.6K153.2K597.3K487.0K-235.3K
Research and development5.21M10.7M12.9M6.31M5.37M4.65M1.46M516.8K
Selling, general and administrative17.8M12.7M24.0M10.0M7.43M3.44M1.77M1.90M2.47M2.20M
Operating income-23.0M-23.8M-30.0M-49.7M-11.4M-8.24M-4.11M-2.79M-3.21M-21.0M
Depreciation and amortization240.0K246.0K103.0K88.0K11.4M10.2M34.8K42.5K55.0K32.3K
EBITDA-22.8M-23.5M-29.9M-49.6M01.95M-4.08M-2.75M-3.16M-21.0M
Interest expense0303.0K3.01K2182.68K9085.2K12.9K50.0K
Income before tax-19.3M-46.9M-18.4M-48.8M-14.9M-8.16M-3.90M-2.87M-3.20M-21.1M
Income tax0030.0K-567.4K-2.68K488.3K-151.6K-262.7K-305.8K
Net income-19.3M-46.9M-18.5M-48.8M-14.9M-8.16M-4.66M-2.72M-2.94M-20.8M
Earnings per share, basic-1.66-40.82-1.15-3.32-1.50-0.33-0.27-0.73-1.55-19.52
Earnings per share, diluted-1.66-40.82-1.15-3.32

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents67.7M15.0M5.86M22.1M37.5M6.85M2.48M93.7K229.6K508.7K
Short-term investments166.6K
Receivables4.63M10.0M287.5K318.8K127.0K284.0K84.3K10.5K8.12K
Inventory-10.0M-416.2K-337.5K-178.1K125.9K153.4K223.8K227.4K
Current assets72.8M20.0M16.2M23.0M38.0M7.01M2.91M384.7K541.9K842.4K
Property, plant and equipment4.00K227.0K472.0K294.0K85.4K97.7K
Goodwill-17.8M
Total assets73.0M20.4M17.0M23.8M38.0M7.01M2.91M520.0K711.5K1.00M
Accounts payable1.13M6.07M527.0K2.63M1.31M175.1K405.5K377.7K497.5K537.6K
Current liabilities1.49M6.98M5.62M2.55M2.02M567.3K736.4K939.0K1.10M774.3K
Total debt96.0K258.0K373.0K784.2K65.3K201.0K398.9K
Total liabilities5.61M7.06M5.83M2.96M2.02M567.3K736.4K939.0K1.10M1.17M
Shareholders' equity67.4M13.4M11.2M20.8M36.0M6.44M2.17M-418.9K-385.3K-169.5K
Shares outstanding12.5M6.48M17.6M15.9M9.93M24.5M17.1M3.73M1.90M1.06M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-12.9M-12.5M-15.8M-10.7M-12.9M-6.87M-3.89M-2.21M-3.00M-2.70M
Capital spending-10.0K-8.00K-277.0K-316.0K-5-4-476.9K-24.5K-50.1K-50.3K
Free cash flow-12.9M-12.5M-16.1M-11.1M-12.9M-6.91M-3.89M-2.19M-3.05M-2.75M
Cash from investing-94.0K-8.00K-277.0K-316.0K-476.9K29.3K12.9K-24.5K-50.1K3.02M
Cash from financing65.9M21.4M08.18M41.2M12.3M7.37M2.10M2.76M183.2K
Dividends paid00
Share buybacks-9.40M0
Change in cash52.9M8.88M-16.1M-2.89M28.4M5.80M3.49M-177.5K-283.4K504.3K

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
ARS · Annual report to shareholdersOct 27, 2026Annual reportSEC
DEFA14A · Additional proxy materialOct 27, 2026Meeting noticeSEC
DEF 14A · Proxy statementOct 27, 2026Meeting noticeSEC
10-K · Annual reportSep 25, 2026Annual reportSEC
8-K · Current reportSep 9, 2026Current reportSEC
8-K · Current reportAug 25, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
8-K · Current reportAug 11, 2026Current reportSEC
8-K · Current reportJul 23, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportJun 25, 2026Current reportSEC
8-K · Current reportJun 10, 2026Current reportSEC
8-K · Current reportJun 9, 2026Current reportSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
8-K · Current reportMay 14, 2026Current reportSEC
8-K · Current reportMay 12, 2026Current reportSEC
8-K · Current reportApr 22, 2026Current reportSEC
8-K · Current reportMar 27, 2026Current reportSEC
8-K · Current reportMar 25, 2026Current reportSEC
8-K · Current reportMar 18, 2026Current reportSEC
8-K · Current reportMar 17, 2026Current reportSEC
424B5 · ProspectusMar 12, 2026Offer documentSEC
8-K · Current reportMar 12, 2026Material contractSEC
8-K · Current reportMar 12, 2026Current reportSEC
8-K · Current reportFeb 25, 2026Current reportSEC
10-Q · Quarterly reportFeb 13, 2026Quarterly reportSEC
8-K · Current reportJan 29, 2026Current reportSEC
8-K · Current reportJan 22, 2026Current reportSEC
8-K · Current reportJan 15, 2026Meeting outcomeSEC
8-K · Current reportJan 15, 2026Current reportSEC
8-K · Current reportJan 14, 2026Current reportSEC
8-K · Current reportDec 18, 2025Current reportSEC
DEFA14A · Additional proxy materialDec 18, 2025Meeting noticeSEC
DEFA14A · Additional proxy materialDec 16, 2025Meeting noticeSEC
8-K · Current reportDec 3, 2025Current reportSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
S-8 · Registration statement for employee plansNov 14, 2025Offer documentSEC
8-K · Current reportOct 30, 2025Current reportSEC
ARS · Annual report to shareholdersOct 27, 2025Annual reportSEC
DEFA14A · Additional proxy materialOct 27, 2025Meeting noticeSEC
DEF 14A · Proxy statementOct 27, 2025Meeting noticeSEC
8-K · Current reportOct 22, 2025Current reportSEC
8-K · Current reportOct 22, 2025Current reportSEC
10-K · Annual reportSep 29, 2025Annual reportSEC
8-K · Current reportAug 26, 2025Current reportSEC
8-K · Current reportAug 22, 2025Current reportSEC
8-K · Current reportAug 8, 2025Current reportSEC
8-K · Current reportJul 31, 2025Current reportSEC
8-K · Current reportJul 30, 2025Current reportSEC
8-K · Current reportJul 25, 2025Current reportSEC
8-K · Current reportJul 24, 2025Current reportSEC
424B5 · ProspectusJul 24, 2025Offer documentSEC
S-3MEFJul 24, 2025Other filingsSEC
8-K · Current reportJun 24, 2025Current reportSEC
8-K · Current reportJun 18, 2025Current reportSEC
8-K · Current reportJun 17, 2025Current reportSEC
8-K · Current reportJun 13, 2025Current reportSEC
8-K · Current reportJun 12, 2025Current reportSEC
S-8 · Registration statement for employee plansJun 4, 2025Offer documentSEC
8-K · Current reportJun 3, 2025Current reportSEC
8-K · Current reportMay 29, 2025Current reportSEC
8-K · Current reportMay 28, 2025Current reportSEC
424B5 · ProspectusMay 28, 2025Offer documentSEC
8-K · Current reportMay 28, 2025Material contractSEC
8-K · Current reportMay 20, 2025Current reportSEC
8-K · Current reportMay 20, 2025Current reportSEC
424B5 · ProspectusMay 20, 2025Offer documentSEC
8-K · Current reportMay 16, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
DEFA14A · Additional proxy materialMay 15, 2025Meeting noticeSEC
8-K · Current reportMay 15, 2025Material contractSEC
8-K · Current reportMay 15, 2025Current reportSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025Current reportSEC
UPLOAD · Letter from the SECApr 29, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 29, 2025Other filingsSEC
424B3 · ProspectusApr 28, 2025Offer documentSEC
DEF 14A · Proxy statementApr 28, 2025Meeting noticeSEC
8-K · Current reportApr 25, 2025Current reportSEC
CORRESP · Letter to the SECApr 24, 2025Other filingsSEC
PRER14AApr 17, 2025Other filingsSEC
S-1/A · Registration statement, amendedApr 16, 2025Offer documentSEC
CORRESP · Letter to the SECApr 16, 2025Other filingsSEC
8-K · Current reportApr 7, 2025Material contractSEC
424B5 · ProspectusApr 7, 2025Offer documentSEC
8-K · Current reportApr 3, 2025Current reportSEC
UPLOAD · Letter from the SECApr 2, 2025Other filingsSEC
UPLOAD · Letter from the SECApr 2, 2025Other filingsSEC
S-3 · Registration statementMar 24, 2025Offer documentSEC
PRE 14A · Preliminary proxy statementMar 18, 2025Meeting noticeSEC
8-K · Current reportMar 18, 2025Material contractSEC
DMar 14, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeMar 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMar 13, 2025Big-stake noticeSEC
8-K · Current reportMar 10, 2025Material contractSEC
8-K · Current reportFeb 14, 2025Current reportSEC
10-Q · Quarterly reportFeb 14, 2025Quarterly reportSEC
8-K · Current reportFeb 4, 2025Current reportSEC
8-K · Current reportJan 23, 2025Current reportSEC
8-K · Current reportJan 10, 2025Current reportSEC
8-K · Current reportDec 11, 2024Meeting outcomeSEC
EFFECT · Notice that a registration is effectiveDec 9, 2024Other filingsSEC
424B3 · ProspectusDec 6, 2024Offer documentSEC
CORRESP · Letter to the SECDec 4, 2024Other filingsSEC
S-1/A · Registration statement, amendedNov 26, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveNov 25, 2024Other filingsSEC
CORRESP · Letter to the SECNov 20, 2024Other filingsSEC
UPLOAD · Letter from the SECNov 15, 2024Other filingsSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
UPLOAD · Letter from the SECNov 13, 2024Other filingsSEC
ARS · Annual report to shareholdersNov 12, 2024Annual reportSEC
DEF 14A · Proxy statementNov 12, 2024Meeting noticeSEC
S-3 · Registration statementNov 6, 2024Offer documentSEC
S-3 · Registration statementNov 6, 2024Offer documentSEC
PRE 14A · Preliminary proxy statementOct 31, 2024Meeting noticeSEC
4 · Change in ownershipOct 24, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 24, 2024Insider tradeSEC
8-K · Current reportOct 24, 2024Current reportSEC
8-K · Current reportOct 24, 2024Management or board changeSEC
8-K · Current reportOct 21, 2024FinancingSEC
8-K · Current reportOct 15, 2024Material contractSEC
8-K · Current reportSep 30, 2024Current reportSEC
10-K · Annual reportSep 30, 2024Annual reportSEC
8-K · Current reportSep 10, 2024Current reportSEC
8-K · Current reportSep 10, 2024Material contractSEC
RW · Request to withdraw a registrationSep 10, 2024Other filingsSEC
8-K · Current reportAug 5, 2024Current reportSEC
5 · Annual statement of ownershipAug 2, 2024Insider tradeSEC
8-K · Current reportJul 30, 2024Current reportSEC
S-1/A · Registration statement, amendedJul 17, 2024Offer documentSEC
S-1 · Registration statementJul 3, 2024Offer documentSEC
8-K · Current reportMay 30, 2024Current reportSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
8-K · Current reportMay 7, 2024Current reportSEC
8-K · Current reportApr 16, 2024Current reportSEC
8-K · Current reportMar 5, 2024Management or board changeSEC
8-K · Current reportFeb 28, 2024Current reportSEC
8-K · Current reportFeb 16, 2024Current reportSEC
10-Q · Quarterly reportFeb 14, 2024Quarterly reportSEC
8-K · Current reportFeb 1, 2024Current reportSEC
8-K · Current reportJan 24, 2024Current reportSEC
8-K · Current reportJan 18, 2024Current reportSEC
8-K · Current reportJan 17, 2024Current reportSEC
8-K · Current reportDec 22, 2023Current reportSEC
4 · Change in ownershipDec 21, 2023Insider tradeSEC
4 · Change in ownershipDec 21, 2023Insider tradeSEC
4 · Change in ownershipDec 21, 2023Insider tradeSEC
4 · Change in ownershipDec 21, 2023Insider tradeSEC
4 · Change in ownershipDec 21, 2023Insider tradeSEC
S-8 · Registration statement for employee plansDec 20, 2023Offer documentSEC
8-K · Current reportDec 15, 2023Current reportSEC
3/A · Initial statement of ownership, amendedDec 8, 2023Insider tradeSEC
3 · Initial statement of ownershipDec 6, 2023Insider tradeSEC
3 · Initial statement of ownershipDec 6, 2023Insider tradeSEC
3 · Initial statement of ownershipDec 6, 2023Insider tradeSEC
3 · Initial statement of ownershipDec 6, 2023Insider tradeSEC
3 · Initial statement of ownershipDec 6, 2023Insider tradeSEC
3 · Initial statement of ownershipDec 6, 2023Insider tradeSEC
3 · Initial statement of ownershipDec 6, 2023Insider tradeSEC
3 · Initial statement of ownershipDec 6, 2023Insider tradeSEC
EFFECT · Notice that a registration is effectiveDec 1, 2023Other filingsSEC
8-K · Current reportNov 29, 2023Material contractSEC
POS AM · Amendment to an effective registrationNov 29, 2023Offer documentSEC
15-12GNov 29, 2023Other filingsSEC
25-NSE/ANov 29, 2023Other filingsSEC
25-NSENov 28, 2023Other filingsSEC
6-K · Report of a foreign issuerNov 24, 2023Current reportSEC
6-K · Report of a foreign issuerNov 20, 2023Current reportSEC
6-K · Report of a foreign issuerNov 16, 2023Current reportSEC
6-K · Report of a foreign issuerNov 16, 2023Current reportSEC
6-K · Report of a foreign issuerNov 16, 2023Current reportSEC
6-K · Report of a foreign issuerNov 8, 2023Current reportSEC
6-K · Report of a foreign issuerNov 7, 2023Current reportSEC
20-F · Annual reportOct 31, 2023Annual reportSEC
6-K · Report of a foreign issuerOct 26, 2023Current reportSEC
6-K · Report of a foreign issuerOct 18, 2023Current reportSEC
6-K · Report of a foreign issuerOct 10, 2023Current reportSEC
6-K · Report of a foreign issuerOct 5, 2023Current reportSEC
6-K · Report of a foreign issuerSep 8, 2023Current reportSEC
6-K · Report of a foreign issuerSep 1, 2023Current reportSEC
6-K · Report of a foreign issuerAug 31, 2023Current reportSEC
6-K · Report of a foreign issuerAug 23, 2023Current reportSEC
6-K · Report of a foreign issuerAug 22, 2023Current reportSEC
6-K · Report of a foreign issuerAug 10, 2023Current reportSEC
6-K · Report of a foreign issuerAug 8, 2023Current reportSEC
6-K · Report of a foreign issuerJul 31, 2023Current reportSEC
6-K · Report of a foreign issuerJul 27, 2023Current reportSEC
6-K · Report of a foreign issuerJul 25, 2023Current reportSEC
6-K · Report of a foreign issuerJul 20, 2023Current reportSEC
6-K · Report of a foreign issuerJul 18, 2023Current reportSEC
6-K · Report of a foreign issuerJul 13, 2023Current reportSEC
6-K · Report of a foreign issuerJul 10, 2023Current reportSEC
6-K · Report of a foreign issuerJul 5, 2023Current reportSEC

This page holds 200 of 267 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Incannex Healthcare Inc.’s releases · as of Sep 24, 2026

Common shares
12,544,627
Fully diluted
12,544,627

Fully diluted

LineSharesAs of
Common shares12,544,627Sep 24, 2026

Share count over time

CountShares
Sep 24, 202612,544,627

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
AdvisorShares Investments LLC168K1.3%US$545KSep 30, 2026
LPL Financial LLC153K1.2%US$496KSep 30, 2026
Millennium64,5030.51%US$209KSep 30, 2026
Citadel53,6350.43%US$174KSep 30, 2026
Hrt Financial LP33,4760.27%US$108KSep 30, 2026
Susquehanna21,9950.18%US$71,264Sep 30, 2026
Jane Street16,3760.13%US$53,058Sep 30, 2026
Commonwealth Equity Services, LLC14,0290.11%US$45,450Sep 30, 2026
Morgan Stanley8,1590.07%US$26,435Sep 30, 2026
Osaic Holdings, Inc.5,7100.05%US$18,483Sep 30, 2026
All 17 holders
HolderSharesOf the companyValueAs of
UBS2,0070.02%US$6,502Sep 30, 2026
Quent Capital, LLC1,9280.02%US$6,247Sep 30, 2026
NewEdge Advisors, LLC777<0.01%US$2,517Sep 30, 2026
Barclays750<0.01%US$2,430Sep 30, 2026
BFC Planning, Inc.33<0.01%US$107Sep 30, 2026
Robinhood Markets, Inc.19<0.01%US$60Sep 30, 2026
Caitong International Asset Management Co., Ltd11<0.01%US$36Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
AdvisorShares Psychedelics ETF60,8680.49%US$229KJun 30, 2026
Fidelity Nasdaq Composite Index Fund9,5640.08%US$32,039May 31, 2026
Total Stock Market Index Trust243<0.01%US$914Jun 30, 2026

Big stakes

StakeStakeSharesDateFiling
Polar Asset Management Partners Inc.7.00%900KJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Lekhram Changoer
Other companies: AXIM Biotechnologies, Inc. (Director · Apr 23, 2015 – Dec 31, 2016 · Past)
Chief Technology Officer · Since at least Nov 28, 2023
George AnastassovBoard Member · Since at least Nov 14, 2025
Joel LathamPresident and Chief Executive Officer · Since at least Nov 28, 2023
Joseph SwanChief Financial Officer · Since at least Nov 28, 2023
Lou BarbatoChief Medical Officer · Since at least May 14, 2026
Luigi M BarbatoChief Medical Officer · Oct 21, 2024 – Oct 23, 2024 · Past
Madhukar BhallaSecretary and CFO · Nov 28, 2023 – Nov 28, 2023 · Past
Mark BleackleyChief Scientific Officer · Since at least Dec 3, 2025
Natalie MayHead of Clinical Operations · Since at least Nov 5, 2026
Parisa AsvadiVice President, Research and Development · Since at least Nov 5, 2026
All 13 people
PersonSeat
Peter WiddowsBoard Member · Since at least Nov 28, 2023
Robert ClarkDirector · Since at least Nov 28, 2023
Troy ValentineDirector · Since at least Nov 14, 2025

Open People

Log in to ask 6ix AI your own questions about Incannex Healthcare Inc.